BioSpace News Archive

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the pricing of its initial public offering of 4,819,277 units at a price of $4.15 per unit.

ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended December 31, 2020.

- Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D -

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock January 28, 2021.

Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18 th , 2021 SAN DIEGO--( BUSINESS WIRE )-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2020 financial results after market close on Thursday, February 18, 2021. Following the release of resu

Digital PCR for COVID-19 wastewater testing overcomes limitations of traditional PCR Wastewater surveillance testing can quantify COVID-19 in populations and track mutations Custom QIAcuity One-Step Viral RT-PCR Kit supports wastewater testing applications